Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Net Asset Quality Index
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Net Asset Quality Index of 62.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $2.86 Million minus total liabilities of $1.06 Million yields net assets of $1.80 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore CVKD total asset value for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Cadrenal Therapeutics, Inc. Common Stock Net Asset Quality Index Over Time (2022–2025)
This chart shows how Cadrenal Therapeutics, Inc. Common Stock's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 62.8%, representing net assets of $1.80 Million against total assets of $2.86 Million USD. See Cadrenal Therapeutics, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Cadrenal Therapeutics, Inc. Common Stock (CVKD) total market value.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 63.3% | $2.74 Million | $4.33 Million | $1.59 Million | ▼ -10.2 pp |
| 2024 | 73.5% | $7.44 Million | $10.12 Million | $2.68 Million | ▼ -16.8 pp |
| 2023 | 90.3% | $7.69 Million | $8.52 Million | $826.88K | ▲ +803.6 pp |
| 2022 | -713.4% | $-5.55 Million | $778.17K | $6.33 Million | — |